Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

49.66EUR
5:25pm IST
Change (% chg)

€0.84 (+1.72%)
Prev Close
€48.82
Open
€48.78
Day's High
€49.95
Day's Low
€48.60
Volume
735,597
Avg. Vol
2,153,691
52-wk High
€71.36
52-wk Low
€38.28

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

UPDATE 2-Fresenius flags faster earnings growth from 2020 after investment

* Announces 1 bln euros share buyback at Fresenius Medical Care

20 Feb 2019

Fresenius expects earnings to stagnate in 2019 as investments weigh

BERLIN, Feb 20 German healthcare group Fresenius said sales growth would slow and profit stagnate this year as investments to fix the performance at its German hospitals business and build up home dialysis take a toll.

20 Feb 2019

Akorn gets FDA warning letter for Illinois plant, shares drop

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

09 Jan 2019

UPDATE 3-Akorn gets FDA warning letter for Illinois plant, shares drop

Jan 9 Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

09 Jan 2019

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE.

08 Dec 2018

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

WILMINGTON, Del Akorn Inc said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE .

08 Dec 2018

Deals of the day-Mergers and acquisitions

Dec 7 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

08 Dec 2018

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w

01 Nov 2018

Fresenius says working to fix performance at dialysis business, German hospitals

BERLIN, Oct 30 Germany's Fresenius said it was putting measures in place to improve growth at its dialysis and German hospitals businesses after a weaker performance of these units prompted the group to narrow its guidance earlier this month.

30 Oct 2018

German stocks - Factors to watch on Oct. 19

BERLIN, Oct 19 The following are some of the factors that may move German stocks on Friday:

19 Oct 2018

Earnings vs. Estimates